Speaker Profile
Ph.D., CSO & Co-Founder, Adaptive Biotech
Biography
Harlan Robins is a CoFounder of Adaptive Biotechnologies, a commercialstage biotech company that aims to translate the genetics of the adaptiveimmune system into clinical products to diagnose and treat disease. Priorto cofoundingconfounding Adaptive, Harlan served in various roles at theFred Hutchinson Cancer Research Center (FHCRC) in the Computational BiologyProgram, including Assistant Faculty Member, Associate, and Full Member andHead of the program. Interested in the mathematics behind genetics andobserving the potential utility of high level mathematics to study problemsin the biological sciences, Harlan took a postdoctoral appointment at theInstitute for Advance Study in Princeton under famed biologist Dr. ArnoldLevine. With Dr. Levine, he concentrated on developing bioinformaticalgorithms for micro RNA targets and bacterial genome analysis, a precursorto his faculty appointment at FHCRC in the Computational Biology Group,Public Health Sciences and Human Biology Divisions.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, Cytoreason
Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, Biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Sanoj Punnen, University of Miami
• Shivanni Kummar, OHSU
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug?
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
